Anti-Tumor Antibodies: MUC16 (CA125)
First-line treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
Bispecific Antibodies: PD-1, LAG-3
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Cellular Therapy
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Checkpoint Inhibitors: CD47
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Checkpoint Inhibitors: CTLA-4
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Partially Pt-Sensitive/Resistant: Treatment given for recurrence occurring 6-12 months or less than 6 months after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Checkpoint Inhibitors: PD-1
Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Partially Pt-Sensitive/Resistant: Treatment given for recurrence occurring 6-12 months or less than 6 months after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Checkpoint Inhibitors: PD-L1
Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
First-line treatment with/without extended (maintenance) treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Checkpoint Inhibitors: PVRIG
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Checkpoint Inhibitors: TIGIT
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Vaccines: Survivin
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Vaccine: Tumor Associated Antigens
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
Anti-Tumor Antibodies: MUC16 (CA125)
First-line treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01616303 | II | Carboplatin, Oregovomab, Paclitaxel | Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma | Addition of oregovomab to carboplatin+paclitaxel significantly increases PFS and OS CarboPt+Pac+Ore vs CarboPt+Pac: PFS: 41.8 vs 12.2 months* pub 2020 |
Bispecific Antibodies: PD-1, LAG-3
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT03219268 | I | Margetuximab, Tebotelimab | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms | Tebotelimab (MGD013) alone or in combination with margetuximab has an acceptable safety profile and shows encouraging early evidence of anti-tumor activity 23 OC in monotherapy expansion Tebotelimab+Margituximab: 41 HER2+ patients, median 2 prior therapies (1-7), 5 OC abs May 2020 and presentation, abs Nov 2020 and poster |
Cellular Therapy
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02498912 | I | 4H11-28z/fIL-12/EFGRt+ CAR T, Cyclophosphamide, Fludarabine | A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors | IV and IP CAR T cell therapy is safe in the absence of chemotherapy, but toxicity is observed when the CAR T cells are given post-lymphodepleting chemotherapy DCR: 44% abs Mar 2020 |
Checkpoint Inhibitors: CD47
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT03558139 | Ib | Avelumab, Magrolimab | A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naive Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy | Magrolimab+avelumab is a novel, well-tolerated combination with a 56% stable disease rate in ovarian cancer patients DCR: 56% (10SD) abs Feb 2020 |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02216409 | I | Magrolimab | A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies | Promising activity with manageable toxicity in OCCC and FTC ORR: 15.4% (n=13) Pub 2019 |
Checkpoint Inhibitors: CTLA-4
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01611558 | II | Ipilimumab | A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects | Ipilimumab shows encouraging anti-tumor activity, but with serious side effects ORR: 10.3% pub 2017 |
Partially Pt-Sensitive/Resistant: Treatment given for recurrence occurring 6-12 months or less than 6 months after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02498600 | II | Ipilimumab, Nivolumab | Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Encouraging anti-tumor activity of ipilimumab+nivolumab combination with favorable benefit over risk Ipi+Niv vs Niv: pub 2020 |
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT04140526 | Ia/Ib | Gotistobart | Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001) | ONC-392 as monotherapy shows encouraging anti-tumor activity in ovarian cancer ORR: 21% abs Nov 2022 and poster |
| NCT03860272 | I | Balstilimab, Botensilimab | A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer | Botenlisimab alone or in combination with balstilimab demonstrates clinical activity in platinum resistant OC. Activity is seen both in patients with the low and high affinity FcγRIIIA alleles, unlike first generation anti-CTLA-4 molecules that generally benefit only those patients who express the high affinity allele Bot: Bot+Bal: abs Nov 2022 and slide from presentation, abs Mar 2023 and presentation |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01975831 | I | Durvalumab, Tremelimumab | A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | Tremelimumab+durvalumab has a manageable safety profile with preliminary evidence of clinical activity in OC ORR: 7.4% abs May 2017 |
Checkpoint Inhibitors: PD-1
Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT03245892 | I | Carboplatin, Nivolumab, Paclitaxel | A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | In high-risk OC patients, addition of nivolumab to neoadjuvant chemotherapy and as maintenance shows promising PFS and favorable changes in the tumor microenvironment 90% achieved optimal cytoreducation at IDS abs Mar 2020 |
First-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02766582 | II | Carboplatin, Paclitaxel, Pembrolizumab | Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer | Pembrolizumab with carboplatin+paclitaxel on a weekly schedule is overall well tolerated and 12 months PFS is promising 28 patients abs Mar 2020 |
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02873962 | II | Nivolumab, Bevacizumab | A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | Encouraging activity of nivolumab+bevacizumab combination ORR: 40% pub 2019 |
| NCT02660034 | I/Ib | Pamiparib, Tislelizumab | A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors | Tislelizumab+pamiparib is well tolerated and associated with antitumor responses in both BRCA WT and BRCA MUT ovarian cancer 16 evaluable Pt-S: pub 2019 |
Partially Pt-Sensitive/Resistant: Treatment given for recurrence occurring 6-12 months or less than 6 months after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02498600 | II | Ipilimumab, Nivolumab | Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Encouraging anti-tumor activity of ipilimumab+nivolumab combination with favorable benefit over risk Ipi+Niv vs Niv: pub 2020 |
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| JapicCTI-153004; NINJA | III | Liposomal doxorubicin, Nivolumab, Gemcitabine | Multicenter, open-label, randomized study in patients with ovarian cancer(ONO-4538-23) | Nivolumab does not improve OS compared with gemcitabine/liposomal doxorubicin in patients with platinum resistant ovarian cancer PFS: 2.0 vs 3.8 months pub 2021 |
| NCT02440425 | II | Paclitaxel, Pembrolizumab | Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer | Pembrolizumab+paclitaxel shows improved ORR and PFS compared to historical results with paclitaxel ORR: 51.4% Press release Feb 2020 |
| NCT02608684 | II | Cisplatin, Pembrolizumab, Gemcitabine | A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | Adding pembrolizumab to cisplatin+gemcitabine and continuing as maintenance treatment results in promising response rates, however the median duration of response is modest and the addition of pembrolizumab does not appear to provide benefit beyond the use of chemotherapy alone in most patients ORR: 61.1% pub 2021 |
| NCT02853318 | II | Bevacizumab, Cyclophosphamide, Pembrolizumab | A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Pembrolizumab+bevacizumab+cyclophosphamide is well tolerated and demonstrates clinical benefit and durable treatment responses ORR: 43.3% pub 2020 |
| NCT02865811 | II | Liposomal doxorubicin, Pembrolizumab | A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | Encouraging anti-tumor activity of pembrolizumab+liposomal doxorubicin with acceptable safety profile ORR: 26.1% pub 2020 |
| NCT02873962 | II | Nivolumab, Bevacizumab | A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | Nivolumab+bevacizumab shows activity in Pt-R patients, independent of PD-L1 expression ORR: 16.7% pub 2019 |
| NCT02901899 | II | Guadecitabine, Pembrolizumab | An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer | Pembrolizumab+guadecitabine has modest activity but some patients experience prolonged disease stabilization ORR: 9.1% abs May 2020 and poster |
| NCT03574779 | II | Dostarlimab, Bevacizumab, Niraparib | A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL) | Triplet therapy with dostarlimab, niraparib, and bevacizumab is tolerable and demonstrates clinical activity in patients with BRCA WT Pt-R OC without HRR gene mutations ORR: 17.9% w/ prior Bev: ORR: 6% abs Mar 2021 |
| NCT03797326 | II | Lenvatinib, Pembrolizumab | A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005) | Pembrolizumab+lenvatinib demonstrates encouraging efficacy and manageable safety in patients with heavily pretreated OC, including those with prior platinum failure and those with previous bevacizumab exposure ORR: 24% abs Sep 2020 |
| UMIN000005714 | II | Nivolumab | A Phase II trial of immunotherapy with an anti-PD-1 antibody in advanced / relapsed, Platinum - resistant Ovarian Cancer | Encouraging anti-tumor activity of single-agent nivolumab with acceptable safety profile ORR: 15% pub 2015 |
| NCT02606305; FORWARD II | Ib/II | Pembrolizumab, Mirvetuximab soravtansine | A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer | Encouraging activity of pembrolizumab+mirvetuximab soravtansine combination in FRalpha+ patients ORR: 30% abs Mar 2018; Oct 2018 |
| NCT02657889; TOPACIO | I/II | Pembrolizumab, Niraparib | Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer (TOPACIO) | Promising activity of niraparib+pembrolizumab in platinum resistant patients independent of BRCA status, HRD status and PD-L1 expression ORR: 21% pub 2019 |
| NCT02799095; ARTISTRY-1 | I/II | Nemvaleukin alfa, Pembrolizumab | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1 | Pembrolizumab with Nemvaleukin alfa (ALKS 4230) is well tolerated with encouraging clinical benefit ORR: 28.6% (n=14) abs Jun 2021 and poster, abs Mar 2022, abs Jun 2022 and presentation |
| NCT03029598 | I/II | Carboplatin, Pembrolizumab | Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Pembrolizumab+carboplatin is well-tolerated and active in recurrent Pt-R OC. A ratio of peripheral T-cell exhaustion to radiographic tumor burden may identify patients more likely to benefit from this chemoimmunotherapy ORR: 10.3%; DCR: 63% pub 2021 |
| NCT04570839 | I/II | BMS-986207, COM701, Nivolumab | A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors. | The combination of COM701 + BMS-986207 + nivolumab is well tolerated and has encouraging durable anti-tumor activity with immune activation in patients with platinum resistant HGSOC and OCCC ORR: 20% abs Nov 2023 and poster |
| NCT02660034 | I/Ib | Pamiparib, Tislelizumab | A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors | Tislelizumab+pamiparib is well tolerated and associated with antitumor responses in both BRCA WT and BRCA MUT ovarian cancer 18 evaluable Pt-R: pub 2019 |
| NCT02054806; KEYNOTE-028 | I | Pembrolizumab | Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors | Pembrolizumab shows encouraging anti-tumor activity with acceptable safety profile ORR:12% pub 2019 |
| NCT03596281; PEMBOV | I | Liposomal doxorubicin, Pembrolizumab, Bevacizumab | An Open-label Phase 1 of Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Platinum Resistant Epithelial Ovarian Cancer | Pembrolizumab+bevacizumab with or without liposomal doxorubicin is well tolerated and demonstrate durable responses in Pt-R OC patients Bev+Pem: Bev+PLD+Pem: abs Nov 2021, abs Jun 2022 and poster |
| NCT03666143 | I | Tislelizumab, Sitravatinib | A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors | Combination treatment with sitravatinib and tislelizumab is manageable and shows promising anti-tumor activity ORR: 26% abs Apr 2021 and presentation |
| NCT03860272 | I | Balstilimab, Botensilimab | A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer | Balstilimab in combination with botenlisimab demonstrates clinical activity in platinum resistant OC. Activity is seen both in patients with the low and high affinity FcγRIIIA alleles, unlike first generation anti-CTLA-4 molecules that generally benefit only those patients who express the high affinity allele ORR: 33% abs Nov 2022 and slide from presentation, abs Mar 2023 and presentation |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02598960 | IIa | BMS-986156, Nivolumab | A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors | Nivolumab+BMS-986156 is safe and has efficacy comparable to historical data reported for nivolumab monotherapy ORR: 2.7% pub 2019 |
| NCT02178722 | II | Epacadostat, Pembrolizumab | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037) | Pembrolizumab and epacadostat combination shows encouraging anti-tumor activity with acceptable safety ORR: 8% abs Jun 2017 |
| NCT02674061; KEYNOTE-100 | II | Pembrolizumab | A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100) | Modest anti-tumor activity of single-agent pembrolizumab with acceptable safety profile ORR: 8.5% pub 2019, abs May 2020 and presentation |
| NCT02964013 | I | Pembrolizumab, Vibostolimab | A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Vibostolimab+pembrolizumab is well tolerated and demonstrates anti-tumor activity in anti-PD-1/PD-L1 naive ovarian cancer patients; particularly in patients with PD-L1 CPS ≥1 ORR: 8% w/ PD-L1 CPS ≥ 1: ORR: 24% abs Apr 2022 and poster |
Checkpoint Inhibitors: PD-L1
Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02726997 | I/II | Carboplatin, Durvalumab, Paclitaxel | Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) | Durvalumab with chemotherapy in upfront ovarian cancer and continued as maintenance is safe and shows reasonable efficacy 83% obtained optimal cytoreduction at surgery abs Apr 2020 |
First-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02718417; JAVELIN Ovarian 100 | III | Avelumab, Carboplatin, Paclitaxel | A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (MSB0010718C) In Combination With And/Or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100 | Avelumab addition to carboplatin+paclitaxel and/or continued as maintenance therapy for newly diagnosed ovarian cancer patients does not improve PFS; PD-L1, CD8, and gBRCA1/2 status did not predict differential clinical benefit CarboPt+Pac+Ave+Ave maint vs CarboPt+Pac+Ave maint vs CarboPt+Pac: ORR: 36.0 vs 30.4 vs 30.4% pub 2021 |
| NCT03038100; IMagyn050 | III | Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel | A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Atezolizumab does not significantly improve PFS or OS in the ITT or PD-L1+ population. The combination is generally well tolerated with manageable AEs; neither BRCA MUT nor HRD+ was associated with greater clinical benefit from adding atezolizumab CarboPt+Pac+Bev+Ate vs CarboPt+Pac+Bev+Placebo: PD-L1+ patients: pub 2021, 2023 |
| NCT03737643; DUO-O | III | Bevacizumab, Carboplatin, Durvalumab, Paclitaxel, Olaparib | A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O). | CarboPt+Pac+Bev+Dur followed by maintenance Bev+Dur+Ola in patients with newly diagnosed non-BRCA MUT advanced OC shows a statistically significant and clinically meaningful improvement in PFS vs CarboPt+Pac+Bev followed by maintenance Bev ITT: HRD+ (excl. tBRCA MUT): HRD-: abs Jun 2023 and presentation |
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02891824; ATALANTE | III | Atezolizumab, Bevacizumab, Carboplatin, Liposomal doxorubicin, Paclitaxel, Gemcitabine | A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab | Atezolizumab does not improve PFS in the overall population or in the patients with PD-L1 positive tumors PFS: 13.5 vs 11.3 months PD-L1+: pub 2023 |
| NCT03598270; ANITA | III | Atezolizumab, Carboplatin, Liposomal doxorubicin, Niraparib, Paclitaxel, Gemcitabine | A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months | Combining atezolizumab with chemotherapy and maintenance niraparib for platinum sensitive recurrent OC does not significantly improve ORR or PFS; no difference in treatment effect according to PD-L1 status CarboPt+Gem/Pac/PLD+Aze w/Nir+Aze maint vs CarboPt+Gem/Pac/PLD+Placebo w/ Nir+Placebo maint: ORR: 45 vs 43% abs Oct 2023 and presentation |
| NCT02734004; MEDIOLA | I/II | Bevacizumab, Durvalumab, Olaparib | A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors | Promising activity of olaparib+durvalumab in gBRCA MUT OC patients; olaparib+durvalumab+bevacizumab shows promising activity in non-gBRCA MUT patients regardless of LOH score and mutation status of common DDR genes Ola+Dur, gBRCA MUT: Ola+Dur, non-gBRCA MUT: Ola+Dur+Bev, non-gBRCA MUT: abs Oct 2019, abs Sep 2020, pub 2020, abs Sep 2022, pub 2024 |
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT03699449 | II | Durvalumab, Olaparib | An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION) | Durvalumab+olaparib shows promising activity in BRCA MUT patients ORR: 35.7% abs Jun 2021 and poster, pub 2022 |
| NCT02580058; JAVELIN Ovarian 200 | III | Avelumab, Liposomal doxorubicin | A Phase 3, Multicenter, Randomized, Open-Label Study Of Avelumab (MSB0010718C) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-Resistant/Refractory Ovarian Cancer | No significant improvement in ORR, PFS or OS with avelumab+liposomal doxorubicin (PLD) compared to avelumab or PLD alone Ave+PLD vs Ave vs PLD: ORR: 13.3 vs 3.7 vs 4.2% pub 2021 |
| NCT02431559 | II | Durvalumab, Liposomal doxorubicin | Phase 1/2 Study of Chemoimmunotherapy With Toll-like Receptor 8 Agonist Motolimod (VTX-2337) + Anti-PD-L1 Antibody MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin is Indicated | Durvalumab+liposomal doxorubicin has a tolerable safety profile and promising efficacy ORR: 22.5% abs Mar 2020 |
| NCT02659384; EORTC-1508 | II | Acetylsalicylic acid, Atezolizumab, Bevacizumab | A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma | The addition of atezolizumab to bevacizumab (with or without acetylsalicylic acid) improves PFS and TFST Bev vs Bev+Ate vs Bev+Ate+Asa: ORR: 24.1 vs 20.7 vs 27.6% abs Sep 2021 |
| NCT04739800; NRG-GY023 | II | Cediranib, Durvalumab, Liposomal doxorubicin, Olaparib, Paclitaxel, Topotecan | A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab | The non-chemo triplet of olaparib, cediranib and durvalumab does not improve PFS compared to standard chemotherapy Ola+Ced+Dur vs TPC (Pac, PLD, or Top): PFS: 2.9 vs 4.3 months abs Oct 2023 and presentation |
| NCT01633970 | Ib | Atezolizumab, Bevacizumab | A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or Chemotherapy in Patients With Advanced Solid Tumors | Atezolizumab+bevacizumab induces durable responses and/or disease stabilization in some patients with Pt-R OC; the safety profiles are consistent with those of each agent ORR: 15% pub 2020 |
| NCT03558139 | Ib | Avelumab, Magrolimab | A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naive Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy | Avelumab+magrolimab is a novel, well-tolerated combination with a 56% stable disease rate in ovarian cancer patients DCR: 56% (10SD) abs Feb 2020 |
| NCT01772004 | I | Avelumab | A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications | Avelumab shows encouraging activity with acceptable safety profile in ovarian cancer ORR: 9.6% pub 2019 |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02484404 | I/II | Cediranib, Durvalumab, Olaparib | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | Promising response rates for durvalumab, cediranib and olaparib in OC Dur+Ola: 34 evaluable: Dur+Ced: 7 evaluable: Dur+Ola+Ced: 7 evaluable: pub 2017; abs Oct 2018, pub 2019 |
| NCT01375842 | I | Atezolizumab | A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies | Atezolizumab shows encouraging activity with acceptable safety profile in PD-L1+ patients 9 evaluable ovarian: pub 2019 |
| NCT01975831 | I | Durvalumab, Tremelimumab | A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | Durvalumab+tremelimumab has a manageable safety profile with preliminary evidence of clinical activity in OC ORR: 7.4% abs May 2017 |
Checkpoint Inhibitors: PVRIG
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT04570839 | I/II | BMS-986207, COM701, Nivolumab | A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors. | The combination of COM701 + BMS-986207 + nivolumab is well tolerated and has encouraging durable anti-tumor activity with immune activation in patients with platinum resistant HGSOC and OCCC ORR: 20% abs Nov 2023 and poster |
Checkpoint Inhibitors: TIGIT
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT04570839 | I/II | BMS-986207, COM701, Nivolumab | A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors. | The combination of COM701 + BMS-986207 + nivolumab is well tolerated and has encouraging durable anti-tumor activity with immune activation in patients with platinum resistant HGSOC and OCCC ORR: 20% abs Nov 2023 and poster |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02964013 | I | Pembrolizumab, Vibostolimab | A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Vibostolimab+pembrolizumab is well tolerated and demonstrates anti-tumor activity in anti-PD-1/PD-L1 naive ovarian cancer patients; particularly in patients with PD-L1 CPS ≥1 ORR: 8% w/ PD-L1 CPS ≥ 1: ORR: 24% abs Apr 2022 and poster |
Immune Cell Stimulators: IDO
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02178722 | II | Epacadostat, Pembrolizumab | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037) | Epacadostat+pembrolizumab combination shows encouraging anti-tumor activity with acceptable safety ORR: 8% abs Jun 2017 |
Immune Cell Stimulators: IL-2R
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02799095; ARTISTRY-1 | I/II | Nemvaleukin alfa, Pembrolizumab | A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1 | Nemvaleukin alfa (ALKS 4230) with pembrolizumab is well tolerated with encouraging clinical benefit ORR: 28.6% (n=14) abs Jun 2021 and poster, abs Mar 2022, abs Jun 2022 and presentation |
Vaccines: NY-ESO-1
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT00887796 | I | Decitabine, Liposomal doxorubicin, NY-ESO-1 protein / MIS416 vaccine | A Phase I Clinical Trial of NY-ESO-1 Protein Immunization in Combination With 5-AZA-2'-Deoxycytidine (Decitabine) in Patients Receiving Liposomal Doxorubicin for Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | Encouraging anti-tumor activity of NY-ESO-1 vaccine+liposomal doxorubicin combination ORR: 10% (n=10) pub 2014 |
Vaccines: Survivin
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02785250; DeCidE1 | Ib/II | Cyclophosphamide, Epacadostat, Maveropepimut-S | A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer | Encouraging anti-tumor activity of immunotherapy combination with limited side effects ORR: 26.3% Patients with Baseline Tumor Burden (BTB) <5 cm: abs Jun 2019 and poster, abs May 2020 and poster, pub 2023 |
Vaccine: TGFbeta
Maintenance after first-line therapy: Treatment to prevent relapse after complete or partial response to therapy
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01309230 | II | Gemogenovatucel-T | Open-label Phase II Trial of Adjuvant bishRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer | FANG vaccine shows encouraging anti-tumor activity and increased RFS with remarkable safety FANG vs Placebo: RFS (from time of procurement, mean/median): pub 2016 |
| NCT02346747; VITAL | II | Gemogenovatucel-T | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy | Vigil immunotherapy as maintenance after first-line therapy in stage III–IV ovarian cancer is well tolerated and shows clinical benefit, particularly for BRCA WT and HRP patients that have high levels of CD39 RNA VIGIL vs Placebo: BRCA WT patients: HRP patients: HRP and CD39 RNA levels above median: pub 2020, pub 2021, pub 2022 |
Vaccine: Tumor Associated Antigens
First-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02107937; SOVO1 | II | DCVAC/OvCa | A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma | DCVAC/OvCa sequential to chemo is associated with a statistically significant improvement in PFS in patients undergoing first-line treatment DCVAC sequential to chemo vs chemo alone: pub 2022 |
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02107950; SOVO2 | II | Carboplatin, DCVAC/OvCa, Gemcitabine | A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma | Significantly prolonged OS with addition of DCVAC/OvCa to carboplatin+gemcitabine Carbo+Gem+DCVAC/OvCa vs Carbo+Gem: PFS: 11.3 vs 10.1 months pub 2021 |